Busan, South Korea

Soung Min Lee

USPTO Granted Patents = 2 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Soung Min Lee: Innovator in Autoimmune Disease Treatment

Introduction

Soung Min Lee is a prominent inventor based in Busan, South Korea. He has made significant contributions to the field of biotechnology, particularly in the treatment of autoimmune diseases and cancer. With a focus on innovative compounds, Lee's work is paving the way for new therapeutic options.

Latest Patents

Soung Min Lee holds 2 patents related to a compound and its use in treating autoimmune diseases. His latest patent describes a compound represented by Formula 1, which may be utilized for treating or preventing various autoimmune diseases, including inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis. Additionally, the compound has potential applications in treating several types of cancer, such as colon cancer, melanoma, and breast cancer.

Career Highlights

Lee is currently associated with Parenchyma Biotech Inc., where he continues to advance his research and development efforts. His work is characterized by a commitment to addressing complex health challenges through innovative solutions.

Collaborations

Some of his notable coworkers include Su Kil Seo and Eun Hye Yoon, who contribute to the collaborative environment at Parenchyma Biotech Inc. Their combined expertise enhances the potential for groundbreaking discoveries in the field.

Conclusion

Soung Min Lee's innovative work in the treatment of autoimmune diseases and cancer exemplifies the impact of dedicated research in biotechnology. His contributions are vital to the ongoing quest for effective therapies, and his patents reflect a promising future in medical advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…